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LEI/L-DNase IILeukocyte Elastase Inhibitor (LEI, also called serpin B1) is a protein involved in apoptosis among other
physiological processes. We have previously shown that upon cleavage by its cognate protease, LEI is
transformed into L-DNase II, a protein with a pro-apoptotic activity. The caspase independent apoptotic
pathway, in which L-DNase II is the ﬁnal effector, interacts with other pro-apoptotic molecules like
Poly-ADP-Ribose polymerase (PARP) or Apoptosis Inducing Factor (AIF). The screening of LEI/L-DNase
II interactions showed a possible interaction with several members of the BCL-2 family of proteins
which are known to have a central role in the regulation of caspase dependent cell death. In this study,
we investigated the regulation of LEI/L-DNase II pathway by two members of this family of proteins:
BAX and BCL-2, which have opposite effects on cell survival. We show that, in both BHK and HeLa cells,
LEI/L-DNase II can interact with BCL-2 and BAX in apoptotic and non-apoptotic conditions. These proteins
which are usually thought to be anti-apoptotic and pro-apoptotic respectively, both inhibit the L-DNase II
pro-apoptotic activity. These results give further insight in the regulation of caspase independent
pathways and highlight the involvement of the intracellular environment of a given protein in the
determinism of its function. They also add a link between caspase-dependent and independent pathways
of apoptosis.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Programmed cell death is a process allowing the elimination of
harmful cells from tissues. During aging, an unbalance of this process
may cause a dysfunction in cell homeostasis which is the basis of many
pathological states, like neurodegenerative diseases or cancer. Among
the different pathways of cell death [1], apoptosis is the best deﬁned. It
is characterized by typical morphological changes, such as chromatin
condensation, DNA fragmentation, membrane blebbing and formation
of apoptotic bodies [2]. The morphological state of apoptosis can beBCL-2 antagonist/killer-1; BAX,
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aubourg Saint-Honoré, 75008achieved by the activation of caspases or non-caspase proteases, in the
so-called caspase independent apoptosis [3].
Concerning caspases, there are two major pathways of caspase
dependent apoptosis: an extrinsic (via the death receptors located to
the plasma membrane) and the intrinsic (mitochondria-associated)
pathways. The mitochondrial pathway is highly regulated by the BCL-2
(B-cell lymphoma 2) family members [4,5]. The BCL-2 family of
proteins is composed of 3 groups of proteins: anti- and pro-apoptotic
members control the permeabilization of the mitochondrial outer
membrane and the BH3-only proteins detect the apoptotic signal and
activate pro-apoptotic proteins like BAX (BCL-2-associated X protein)
or BAK (BCL-2 antagonist/killer-1). This activation allows BAX homo-
oligomerization and pore formation in the mitochondrial membrane
through which pro-apoptotic factors will be released [6,7]. The process
of pore formation is tightly controlled by the anti-apoptotic members
of the BCL-2 family. They antagonize pro-apoptotic members by a
complex interplay of protein–protein interactions [5].
The BCL-2 proteins have been extensively analysed in the frame-
work of mitochondrial membrane permeabilization, irrelevantly of
caspase activation [8–10]. However, mitochondria are not systematical-
ly involved in cell death [11–15]. This is the case of the LEI/L-DNase II
pathway, which depends on the activation of serine and lysosomal
proteases [16–22]. LEI (Leukocyte Elastase Inhibitor) is a cytosolic serine
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into an endonuclease, the L-DNase II (LEI-derived DNase II), and
translocated to the nucleus where it degrades DNA [23,24].
From the data obtained so far, it seems that L-DNase II activation
strongly depends on the apoptotic stimulus; L-DNase II is easily
induced by metabolic but not by genotoxic stresses. For instance,
the LEI/L-DNase II pathway is activated by HMA (Hexamethylene
Amiloride), a Na+/H+ exchanger inhibitor that induces an intracel-
lular pH acidiﬁcation. Other stimuli, like etoposide (cytotoxic
agent), are not able to induce this transformation [21]. Actually, LEI
overexpression experiments conﬁrm its pro-apoptotic effect in
HMA-induced apoptosis and show that LEI protects cells from
etoposide-induced apoptosis, which is caspase-mediated [25].
Indeed, it is likely that the pro- or anti-apoptotic effects of LEI and its
derived species depend both on molecular events leading to the
molecular transformation of LEI into L-DNase II and on the interaction
of these molecules with other apoptotic pathways, including their
regulating molecules. A screening of protein–protein interactions
between LEI and cellular proteins involved in apoptosis was performed
in our laboratory revealing several candidates to LEI/L-DNase II
regulation [26]. Among them, several members of the BCL-2 family
showed some afﬁnity for LEI suggesting an interaction between LEI and
this family of proteins, yielding the hypothesis that the LEI/L-DNase II
pathway may be regulated by BCL-2 and related proteins.
In this study, we investigate the putative interaction between LEI
and the BCL-2 family of proteins in order to investigate if this caspase
independent pathway can also be modulated by BCL-2 and related
proteins. As this family of proteins involve at least 22 members, we
concentrated on the two best studied proteins having opposite effects
on cell survival: BCL-2 and BAX.
2. Materials and methods
2.1. Cell lines and culture conditions
BHKcells (babyhamster kidney)were grownasmonolayer at 37 °C in
humidiﬁed atmosphere containing 5% CO2. BHK were cultured in DMEM
glutamax (Dulbecco's Modiﬁed Eagle's Medium, Gibco) supplemented
with 10% Fetal Calf Serum (FCS) and 0.5% of streptomycin/penicillin
(10,000 IU/mL) (all reagents were from Celbio).
HeLa cells (S3 clone) were cultured in DMEM (Dulbecco's Modiﬁed
Eagle Medium) with GlutaMAX™, supplemented with 4.5 g/L
(25 mM) of D-Glucose, 0.11 g/L (1 mM) Sodium Pyruvate, 10% FCS
and 0.5% penicillin/streptomycin at 37 °C under 5% CO2 and 90% of
relative humidity.
2.2. Cell death induction
BHK and HeLa cells were seeded at a density of 20,000 cells/cm2,
maintained in culture for 2 days and then treated for 18 or 24 h
with different inductors of apoptosis. Cells were treated with 5-(N,
N-hexamethylene) amiloride (HMA; stock solution: 40 mM in DMSO,
Sigma-Aldrich, A9561) at 40 μM for 18 h. As a positive control of
caspase dependent apoptosis, cell cultures were incubated for 3 h
with the topoisomerase II inhibitor, etoposide (Sigma-Aldrich, E1383),
at 100 μM. Thereafter, the drugwas removed and cells weremaintained
in culture with a fresh medium for 24 h. In some experiments, cells
were treated with staurosporine at 1 μM for 18 h (Sigma).
2.3. Pull down assay
Recombinant proteins (wild-type LEI, and calmodulin) were pro-
duced in Escherichia coli strain BL21/pLysS and loaded into His-select
cartridges (Sigma) according to the manufacturer's protocol. Brieﬂy,
the E. coli BL21(DE3)pLysS strain (Promega) was transformed with a
pET 23d(+) plasmid (Novagen) coding for pig LEI with a 6xHis tag.Cultures were grown in L-Broth containing 34 μg/mL chloramphenicol
and 50 μg/mL ampicillin. The expression of the protein was induced
when the optical density at 600 nm was 0.6 by the addition of 1 mM
isopropyl-1-thio-β-D-galactopyranoside (IPTG, Boehringer, Mannheim)
for 2.5 h. Proteins were then extracted with a binding buffer (5 mM im-
idazole, 0.5 mM NaCl, 20 mM Tris–HCl pH 7.9). The protein was then
bound to a Ni-NTA column (Sigma).
HeLa cells were grown to conﬂuence in 75-cm2 ﬂasks before lysis
in RIPA buffer (50 mM Tris [pH 7.2], 150 mM NaCl, 1% Triton X-100,
1% sodium deoxycholate, 1% sodium dodecyl sulfate, 1 mM
phenylmethylsulfonyl ﬂuoride, 1 μg/mL leupeptin, 5 μg/mL pepstatin,
5 μg/mL aprotinin) and loaded onto the column. After washing, the col-
umnswere eluted with 1M imidazole, 0.5 MNaCl, and 20mMTris–HCl
pH 7.9. In this way the protein bound to the column matrix by the tag
together with the interacting proteins were eluted. Samples were
dosed and resolved by sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis and immunoblotted for BCL-2, BAX, BID, and BCL-XL. Cal-
modulin was used as a negative control, and a crude extract of HeLa
cells was used as a positive control. Immunoblots were developed by
using the following antibodies: BAD: Santa Cruz C7, sc-8044, BCL-XL:
Santa Cruz H5, sc-8392, BID: Santa Cruz C20, sc-6538. LEI/L-DNase II:
polyclonal anti-rabbit prepared in the laboratory, BCL-2: Santa Cruz,
N19, sc-492, BAX: Santa Cruz, N20 sc-493. Experiments were done at
least 3 times.
2.4. Co-immunoprecipitation
Co-immunoprecipitation was performed by using the ProFound™
Mammalian Co-Immunoprecipitation Kit (Pierce) in which the anti-
body was covalently immobilized onto an amine-reactive resin. Before
CO-IP, we prepared puriﬁed IgG LEI (rabbit) with a DEAE anion-
exchange column (Wathman) followed by afﬁnity chromatography on
a home-made afﬁnity column. Commercially available anti-BAX and
anti-BCL-2 IgGs were also puriﬁed by afﬁnity chromatography. 100 μg
of proteins fromHeLa cell extractswas loaded per experiment. The eluted
material was then denatured in Laemmli buffer and analysed byWestern
blot with LEI, or BCL-2, or BAX antibody, using the antibodies described
before. The column without IgG was used as a negative control.
2.5. Glycerol gradient
107 BHK or HeLa cells were recovered after 24 h of induction of apo-
ptosis with either etoposide or staurosporine at the concentrations de-
scribed above. Cells were lysed with 750 μL of lysis buffer (20 mM
Hepes, 150 mM NaCl, 0.5 mM DTE). The preparation was sonicated 10
times for 10 s, waiting 15 s between each pulse. 0.2% Triton X-100 was
added to each sample and cleared by centrifugation for 10 min at
15,000 g. The supernatant is layered on top of a continuous linear glycerol
gradient (40% to 5% glycerol in 20mMHepes, 150mMNaCl, and 0.5 mM
DTE, 0.2% Triton X-100). The tubes were centrifuged in a Kontron T-1065
ultracentrifuge at 100,000 g for 18 h. The protein fractions were then
recovered by a hole at the bottom of the tube (5 drops each fraction).
The different fractions were then analysed byWestern blot. The gradient
was calibrated using the following proteins: cytochrome c (12.4 kDa),
carbonic anhydrase (29 kDa), albumin (66 kDa), alcohol dehydrogenase
(150 kDa), and beta-amylase (200 kDa). All proteins were from Sigma
(MWGF 200).
2.6. Immunocytochemistry
BHK and HeLa cells were seeded in coverslips placed at the bottom
of a 12-multiwell plate at the density of 5 × 104 cells/mL in 2ml of com-
pletemedium. 48h after seeding theywere treated as before. At the end
of incubation cells were washed twice with PBS (19 mM Na2HPO4,
1 mM KH2PO4, 140 mM NaCl, 15 mM KCl pH 7.5) containing Ca2+
and Mg2+, ﬁxed with 4% paraformaldehyde for 15 min (all steps were
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Permeabilization was performed by incubation with 0.3% Triton X-100
for 20 min. The cells were then washed twice with PBS. Non-speciﬁc
binding sites were blocked by 1 h incubation in a blocking buffer
containing 1% non-fat milk in PBS. Cells were then incubated with
anti-BAX, anti-BCL-2, or anti-LEI/L-DNase II antibodies at a 1/100
dilution, in 0.1% non-fat milk in PBS for 1 h. For these experiments, we
used the same antibodies than before, except for some experiments in
which the anti-LEI was from chicken origin, also produced in our
laboratory. This was followed by two washes with PBS and incubation
for 1 h with a 1/500 dilution of anti-rabbit Alexa Fluor ® 546 conjugated
antibody, or anti-rabbit Alexa Fluor ® 488 conjugated antibody, or anti-
chicken Alexa Fluor ® 488 conjugated antibody (Invitrogen). Cells
were ﬁnally washed twice with PBS, incubated for 1 min with 4,6 di-
amidino-2-phenyl indole dichloride (DAPI) 1/5000 (Sigma-Aldrich)
and washed three times with PBS. Coverslips were mounted on
microscope slides with ﬂuoromount (SIGMA). Immunoreactivity was
visualised using an Olympus microscope BX51 or a Zeiss LMS710
confocal microscope.
2.7. Stable overexpression of LEI, BCL-2 and BAX
To perform overexpression experiments, BHK cells were transfected
with pREP-LEI, pcDNA-BCL-2, or pCEP4-BAX using an AMAXA® cell line
nucleofector device. pREP-LEI was a home-constructed vector [24]
while BCL-2 and BAX vectors were obtained from Addgene (plasmids
n°18003 for BCL-2 and 16587 for BAX). Transfected cells were selected
by using hygromycin B (SIGMA) (400 μg/mL) for LEI and BAX, or neo-
mycin (SIGMA) (400 μg/mL) for BCL-2. Cells obtained after transfection
were analysed by Western blot to conﬁrm the protein overexpression.
2.8. Flow cytometry
Transfected cells were seeded in 12 wells plates 48 h before
treatment with HMA. After treatment, cells were trypsinized and
resuspended in regular medium. The cell viability was analysed on
Guava easyCyte™ Flow Cytometer with excitation at 488 nm and
emission measured at 575 and 640 nm by using the ViaCount software.
This assay uses a proprietary mixture of two DNA binding dyes to pro-
vide detection of viable, apoptotic and dead cells (Millipore 4000-0040).
2.9. Western blot
Protein concentration was assessed by the BCA method (Pierce)
according to the manufacturer's instructions. After dilution of samples
with Laemmli buffer, 25 μg of the extracted proteins was separated by
12% SDS-PAGE, immobilized on nitrocellulose membrane (PROTAN ®,
Whatman ®) and blotted with: anti-BAX, anti-BCL-2, anti-Actin (Santa
Cruz, I19, Sc-1616), anti-Lamin B (Santa Cruz, C20, sc-6216) at 1/500
dilution, and anti-LEI/L-DNase II (produced in our laboratory [27]) at
1/1000 dilution. The secondary antibodies conjugated to HRP (Vector)
were used in a 1/5000 dilution. Finally, SuperSignal®West Pico Chemi-
luminescent Substrate (Thermo Scientiﬁc)was used to reveal the signal.
2.10. Preparation of sub cellular fractions
For detection of BAX, BCL-2 and LEI/L-DNase II redistribution after
treatment, both cytosolic and nuclear fractions were isolated. Cells
were seeded in a 75 cm2 Falcon bottle and treated as before. After treat-
ment, attached and ﬂoating cells were collected by scrapping and
washed 2 times in cold PBS (every time at 370 ×g, 5 min at 4 °C). Cells
were then resuspended in an ice-cold hypo-osmotic solution of
1.5 mMMgCl2. After mechanical breakage of cell membranes by using
a tight-ﬁt Dounce B potter (10–15 strokes), they were centrifuged and
cytoplasmic fractions contained in the supernatants were collected.
Pellets were washed 2 times with the MgCl2 solution and resuspendedin 100 μL of the M-PER extraction reagent (Pierce 78503). Finally,
protein measurement was performed with bicinchoninic acid (BCA)™
Protein Assay Kit (Thermo Scientiﬁc) using bovine serum albumin
(BSA) as standard. Finally, a Laemmli buffer was added for Western
blot analysis. Anti-actin was used as loading reference, unless otherwise
stated.
2.11. Mitochondrial fractions
Mitochondrial fractions were prepared by using the Mitochondrial
Isolation Kit for tissue from Pierce, according to the manufacturer's in-
structions. The fractions were analysed by Western blot as before.
Mitochondrial fraction was identiﬁed by using an antibody directed
against the Voltage dependent active channel (VDAC) (Santa Cruz,
N18, sc-8828).
2.12. Statistics
One way analysis of variance (ANOVA) was used unless otherwise
stated.
3. Results
3.1. Characterization of the interaction between LEI/L-DNase II and BCL-2,
LEI/L-DNase II and BAX
Our laboratory has discovered and characterized a caspase-
independent pathway of cell death, the LEI/L-DNase II [24]. In order to
get more light on the cellular control of this pathway we investigated
the LEI-interacting proteins by using an Affymetrix interaction mem-
brane (not shown). The experiments revealed a possible interaction
with proteins of the BCL-2 family. Some of these interactions were
veriﬁed by pull down. To do this we prepared recombinant His-tagged
LEI that was loaded on a Ni column. Afterwards, a whole extract of
HeLa cells was charged and LEI, together with its interacting protein,
was eluted from the column. Fig. 1A shows the pull down of BAD,
BCL-XL and BID, while panels B and C show the same experiment for
BAX and BCL-2. These results indicated that several members of the
BCL-2 family could interact with LEI. From the different members of
this family we choose to study more in detail the most known anti
and pro-apoptotic members, BCL-2 and BAX. Experiments were
performed on HeLa cells, cancer cells from human origin and on BHK
cells, ﬁbroblast from hamster origin, in order to assess the general
character and speciﬁcity of interactions.We ﬁrst veriﬁed the interaction
of these proteins with LEI/L-DNase II by performing pull down experi-
ments. Fig. 1B shows a Western blot of a HeLa cell extract after elution
from a LEI loaded column, developed with an anti-BCL-2 antibody. Ctl
represents the control cell extract. An His-tagged calmodulin was used
as a negative control. Fig. 1C shows a representative image of the
same type of experiment performed by using anti-BAX to develop the
Western blot. These results indicated that the LEI/L-DNase II protein is
able to bind BCL-2 and BAX in vitro.
Pull down experiments offered high concentrations of bite pro-
tein, a condition that could force a weak interaction. To conﬁrm the
possibility of these interactions at real cellular concentrations co-
immunoprecipitations of the proteins of interest were performed.
Western blot analysis of these experiments revealed that BCL-2
was co-immunoprecipitated with an anti-LEI antibody and LEI was
co-immunoprecipitated with an anti-BCL-2 antibody (Fig. 1D).
Non-speciﬁc protein interactions were detected in the column with-
out IgG (negative control). In parallel Western blot analysis of
co-immunoprecipitaiton experiments using anti-LEI and anti
BAX revealed that BAX was co-immunoprecipitated with an
anti-LEI antibody and LEI was co-immunoprecipitated with an
anti-BAX antibody (Fig. 1E). Here again, non-speciﬁc protein interactions
were detected in the column without IgG (negative control). Results
Fig. 1. The interaction between LEI/L-DNase II, BCL-2 and BAX. Panel A: Recombinant LEI
harbouring anHis-tagwas produced in Escherichia coli, puriﬁed and ﬁxed on anNickel col-
umn. This LEI afﬁnity column was used to pull down BAD, BCL-XL and BID from a whole
extract of HeLa cells. A column charged with an His-tagged calmodulin, a naive protein,
was run in parallel as a negative control (Cal). A crude extract of HeLa cells was used as
a positive control (Ctl). Panel B: shows a similar experiment in which the material eluted
from the LEI columnwas developedwith an anti-BCL-2 antibody. Panel C: the same exper-
iment than B but an anti-BAXwas used to develop the membrane. Panel D: Extracts from
HeLa cellswere immunoprecipitatedwith anti-LEI/L-DNase II (LEI) or anti-BCL-2 antibody
(BCL-2). An unloaded column was used as a negative control. The obtained proteins were
then developed by Western blot using anti LEI/L-DNase II (upper panel) or anti-BCL-2
(lower panel). Panel E: the same experiment than in D but anti-BCL-2 was replaced by
anti-BAX. LEI/L-DNase II co-immunoprecipitates with BAX and BCL-2. These are represen-
tative results from 3 different experiments.
Fig. 2. LEI/L-DNase II, BCL-2 and BAX co-sediment in a glycerol gradient. HeLa cell extracts
from untreated or treated cells with staurosporine or etoposidewere loaded onto of a lin-
ear glycerol gradient. 25 fractionswere collected from the bottomof the tube and analysed
by immunoblotting with anti-LEI, BCL-2 or BAX antibodies. A zone of co-migration of LEI
with BCL-2 or BAX is always found in apoptotic and control conditions.We show represen-
tative results from 3 to 4 experiments. The gradient was calibrated using MW standards
(see Materials and methods).
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obtained with BHK cells (not shown). This result suggested that these
physical interactions were not cell type speciﬁc.
To further verify these interactions and their possible modiﬁca-
tion during apoptosis, we used a glycerol density gradient loaded
with a whole cell extract from cells (Fig. 2). The cells were left un-
treated or treated with staurosporine (that activates L-DNase II
[19]) or etoposide (that activates caspases but not L-DNase II [25]).
BHK or HeLa cell extracts were loaded onto the top of a linear glycer-
ol gradient separated by centrifugation. 25 fractions were collected
from the bottom of the gradient and analysed by immunoblotting
with anti-LEI, BCL-2 and BAX antibodies. As seen on Fig. 2, in extracts
from HeLa cells, induced or not for apoptosis, a zone of co-migration
of LEI with BCL-2 or BAX was always found. BHK cells showed the
same co-migration of molecules (not shown). In control cells, LEI
and BCL-2 (but also LEI and BAX) co-sedimented in 6 fractions in
the middle of the gradient, suggesting that they belonged to com-
plexes of various sizes. The glycerol gradient using apoptotic cells
also revealed that LEI, BCL-2 and BAX co-sedimented. Indeed, al-
though the absolute distribution of the molecules changed with
treatment, this change was the most important for LEI. This molecule
largely spammed over the gradient on etoposide treated cells while
it was found only in three fractions in the gradient of staurosporine
treated cells. The gradient proﬁle of BCL-2 and BAX was also affected
by different apoptotic treatments but in a lesser extent.
These results indicated that LEI/L-DNase II and BCL-2, as well as
LEI/L-DNase II and BAX could be associated with each other andprobably with other proteins in apoptotic and non-apoptotic
conditions. Of note, in control conditions, LEI showed a single band
of 42 kDa corresponding to the native molecule. In staurosporine
treated cells a band of 35 kDa, corresponding to L-DNase II [24] and
spamming only 3 fractions of the gradient was seen. The distribution
of the protein dramatically changed again in etoposide treated cells
where the 42 kDa species largely spammed the gradient. A very
faint band of L-DNase II was seen in heavier fractions.
Concerning BCL-2, the induction of apoptosis also modiﬁed its
pattern. Staurosporine treated cells showed an almost identical
distribution as the control cells but a second band of an apparent
molecular weight of 46 kDa, probably a BCL-2 dimer [28], was detected.
The distribution pattern of BCL-2 completely changes when cells were
treated with etoposide. An important part of BCL-2 moved to the
bottom of the gradient and a 20 kDa fragment appeared, probably
corresponding to the caspase 3 or 8 generated fragment [29,30].
For BAX, the 18 kDa band, corresponding to its monomer, was found
in all gradients. Upon induction of apoptosis with staurosporine or
etoposide, there were two additional bands. The band of 42 kDawas al-
ready described as the homodimer of BAX that forms duringmitochon-
drial permeabilization in caspase dependent apoptosis [10] as well as a
band corresponding to 26 kDa that was also detected.
Taken together these data indicated that LEI/L-DNase II could
interact with these two proteins of the BCL-2 family. However, even
though this interaction was molecularly possible, the molecules should
be able to physically interact in the cell. This is why the cellular localization
of the different partners was investigated.
Fig. 3. Immunolocalization of LEI/L-DNase II, BCL-2 and BAX. Panel A: Immunolocalization of LEI and BCL-2 in control and treated HeLa cells with Staurosporine (sts), HMA (HMA) or
etoposide (eto). LEI/L-DNase II shows a cytoplasmic labelling in control cells and a nuclear labelling in cells treated with HMA or staurosporine, indicating the activation of the LEI/L-
DNase II. In contrast, LEI is cytoplasmic in etoposide treated cells. BCL-2 is located in the same compartments than LEI in all conditions. Scale bars represent 20 μm. Panel B: Fluorescence
proﬁles of control (Ctr) and HMA treated cells of panel A. The ﬂuorescence plot in the axis of control and HMA conditions seen in Panel Awas calculated using the Fiji GNU software. Panel
C: Immunolocalization of LEI and BAX in control and treated BHK cells, with staurosporine (sts), HMA (HMA) or etoposide (eto). LEI and BAX labellings were cytoplasmic. In contrast, L-
DNase II and BAX labellingwere nuclear in apoptotic cells treatedwith HMA or staurosporine. Scale bars represent 20 μm. Panel D: Fluorescence proﬁles of control and HMA treated cells.
The ﬂuorescence plot in the axis of control and HMA conditions seen in Panel C was calculated using the Fiji GNU software. Panel E: Nuclear and cytoplasmic fractions from HeLa cells
treated with HMA (HMA) or untreated (control) were analysed by Western blot using anti-LEI/L-DNase II and anti-BAX antibodies. A cytoplasmic localization of LEI and BAX in control
cells was seen. In contrast, the nuclear fraction of HMA treated cells showed L-DNase II and also BAX. Actin was used as a control of charge, lamin B as a control of nuclear puriﬁcation.
The histogram seen on the right shows a quantiﬁcation of nuclear BAX proteins expressed as a ratio to actin. Values are signiﬁcantly different p b 0.05 according to the t test.
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Once the physical afﬁnity between molecules demonstrated, it was
necessary to verify if these interactions were possible in the cell by
studying the cellular localization of LEI/L-DNase II, BCL-2 and BAX in
HeLa and BHK cells. In Fig. 3, immunocytochemistry was used to verify
their subcellular localization in normal and apoptotic cells. In normal
HeLa cells, LEI and BCL-2 localized at the cytoplasm. In cells treated
with HMA or with staurosporine, there was a nuclear translocation of
L-DNase II and BCL-2. In contrast, LEI remained cytoplasmic in cells
treated with etoposide which was not able to activate the LEI/L-DNase
II pathway (Fig. 3, panels A and B). In all circumstances a localization
in the same compartment of BCL-2 and LEI was observed.
Concerning BAX, in both control cells and etoposide-treated, LEI and
BAXwere localized at the cytoplasm. Thepunctuated staining suggested
a partial mitochondrial localization. In contrast, L-DNase II and BAX
were translocated to the nucleus in apoptotic cells treated with HMA
or staurosporine (Fig. 3, panels C and D).
The nuclear localization of BAX after treatment with HMA
seemed important. As this was an unusual situation, we veriﬁed this
result by analysing nuclear fractions. A cytoplasmic-nuclear fraction-
ation of HeLa cells analysed by Western blot conﬁrmed the presence
of L-DNase II and BAX in the nuclear fraction of HMA-treated cells that
further supported the nuclear translocation of BAX in this apoptotic
pathway (Fig. 3E). Note that the WB presented here is not comparable
to the results presented in panel 3A. Here the same amount of protein
was loaded in each well. As nuclear protein represents 5–10% of the
total cellular proteins, the “nuclear” fractions corresponded to a higher
number of cells than the cytoplasmic fractions. The same results were
obtained with BHK cells (not shown). Taken together, all these results
suggested that LEI could interact with BAX and BCL-2 in different condi-
tions, whether the cell was alive or dying.
3.3. The effect of LEI-BCL-2 and LEI-BAX interactions on cell survival
To estimate the functional impact of these interactions on cell
survival, overexpression, using stable transfection techniques, of LEI,
BCL-2 or BAX was made in BHK and HeLa cells. Not targeted
proteins were preferred in order to avoid alterations in their speciﬁc
activities introduced by the tag. The three proteins (BCL-2, BAX and
LEI) were overexpressed separately or in co-transfection, LEI-BCL-2,
and LEI-BAX. Protein expression was veriﬁed by Western blot (not
shown). After establishing permanent clones, cells were treated with
HMA for 18 h. These conditions were selected in order to have a rate
of apoptosis allowing to easily identify a modiﬁcation of cell viability.
Cell viability was then measured by ﬂow cytometry.
In cells transfected with BCL-2 alone, the rate of cell death was
decreased compared with non-transfected control cells (Fig. 4A). This
is the classical anti-apoptotic effect of BCL-2, widely described in the
literature. In contrast, the overexpression of LEI induces the death of
more than 50% of cells which conﬁrms the pro-apoptotic effect of LEI
in this condition of apoptosis. In cells co-expressing LEI and BCL-2,
BCL-2 protected against cell death induced by LEI and seemed able to
counter the pro-apoptotic effect of the L-DNase II.
Concerning BAX overexpression, it induced an important increase in
cell death, which conﬁrmed the pro-apoptotic effect of this protein
largely described in the literature (Fig. 4B). Surprisingly, in cells with
co-expression of LEI and BAX, therewas a decrease of cell death induced
byHMA suggesting that the pro-apoptotic effects of themolecules were
mutually invalidated; e.g. simultaneous overexpression of BAX and LEI
apparently cancelled the pro-apoptotic effects of the two proteins,
returning to a cell death level similar to the one observed in non-
transfected BHK cells. To investigate this protective effect of
simultaneous overexpression of LEI and BAX,we studied the subcellular
localization of these two proteins in the different transfected cells by
immunocytochemistry (Fig. 4C). In all control cells, LEI and BAX localizeat the cytoplasm. After treatment with HMA, in non-transfected cells
and in cells overexpressing LEI, these two proteins were translocated
to the nucleus. In contrast, cells overexpressing BAX and both LEI and
BAX, showed a perinuclear localization of LEI and BAX, suggesting that
the freely nuclear distribution of LEI was impaired. These results were
conﬁrmed by nuclear puriﬁcation and Western blot (Fig. 4, panel D).
Because the degree of freedom of LEI in the cytoplasm could be
involved in the mechanism of control of this pathway by BCL-2, we
investigated the distribution of this protein in cytoplasmic and mito-
chondrial fractions (Fig. 5). In this case, we investigated the mitochon-
drial compartment because this is where BCL-2 is involved in cell
survival. We found that LEI was almost evenly distributed between
cytoplasmic and mitochondrial fractions in control cells (Fig. 5A). The
induction of apoptosis by a caspase activating agent (etoposide) did
not modify this distribution. However, the activation of L-DNase II
with staurosporine or HMA clearly mobilized the LEI cytoplasmic pool
(Fig. 5A). The expression of BCL-2 changed this distribution (Fig. 5B).
In cells overexpressing BCL-2, an important amount of LEI was retained
at themitochondria after induction of apoptosis and themobilization of
the cytoplasmic pool was less important.
4. Discussion
In this paper we show that LEI/L-DNase II interacts with BCL-2
family members in apoptotic and non-apoptotic conditions. The
BCL-2 family of proteins has a central role in the regulation of
caspase dependent cell death. Our results indicate that caspase inde-
pendent cell death mediated by LEI/L-DNase II can also be regulated
by this family of proteins. It is interesting to note that the interaction
BCL-2/LEI/L-DNase II is protective, conﬁrming the already known
anti-apoptotic function of BCL-2 [4,5,8]. However the interaction
with the classical pro-apoptotic protein BAX seems not to have the
expected effect and turns out to be protective in L-DNase II mediated
apoptosis. This highlights the involvement of intracellular environ-
ment of the protein to the determinism of its function.
Many studies have been done to understand the molecular mecha-
nisms controlling cell death. The BCL-2 family of proteins is thought to
be a key player in the regulation of mitochondrial membrane perme-
abilization (MMP) and thus a knob in caspase dependent apoptosis
[31]. Other than cytochrome C that triggers apoptosome formation,
the MMP will also induce the release of other caspase-independent
apoptotic factors like AIF [32,33], HrtA/Omi [34] or endonuclease G.
However, MMP is not involved in all apoptotic cell death [3,35–39].
We have characterized the LEI/L-DNase II, a caspase independent
pathway activated by serine proteases and cathepsins, and involved in
the death of many cellular types, either in vivo or in vitro [23,24]. This
pathway uses cytoplasmic effectors and does not requireMMP. Though,
the interaction of this molecule with proteins regulating MMP does not
seem necessary per se. However, we show here that LEI can interact
with BCL-2 and BAX in apoptotic and non-apoptotic conditions. Themo-
lecular interaction has been demonstrated using several approaches:
pull down, co-immunoprecipitation and glycerol gradient, suggesting
the existence of a robust interaction between these proteins. Note that
the glycerol gradient shows a constant co-fractionation of themolecules
of interest, although their position in the gradient highly depends on the
cell treatment. Although cells treated with etoposide or staursoporine
both die and show an apoptotic phenotype, the distribution of the stud-
ied molecules highly differs, indicating that they belong to different
complexes and thus that the molecular events occurring in each situa-
tion are different. Moreover, these molecular interactions are seen in
control conditions, as well as in HMA treated cells, where the intracellu-
lar pH is decreased, suggesting that the interaction of LEI with the BCL-2
family members is independent of the intracellular acidiﬁcation.
The co-localization study by immunocytochemistry conﬁrms that
the two couples of proteins are found in the same cellular compartment
with all the treatments studied so far, suggesting that the interactions
Fig. 4. BCL-2 and BAX protect against cell death induced by L-DNase II: Panel A: BCL-2 and LEI were overexpressed separately or together in BHK cells. Cell viability was evaluated by ﬂow
cytometry using the Viacount method (Guava, Millipore) after treatment with 40 μMHMA for 18 h. In cells overexpressing BCL-2, the mortality rate was decreased compared with non-
transfected cells. In contrast, the over-expression of LEI induces the death of more than 50% of cells in cells co-expressing LEI and BCL-2. BCL-2 protects against cell death induced by LEI/L-
DNase II. NT represents cells expressing the empty vector. Fig. 4A shows representative experiment out of 5 experiments. All differences are statistically signiﬁcant according to the one
way ANOVA test p b 0.001. Panel B: These experiments were conducted as in panel A. The proteins overexpressed were LEI and BAX. The over-expression of BAX induced an important
increase in cell death. In cells co-expressing LEI and BAX, the pro-apoptotic effect of LEI is lost. NT represents cells expressing the empty vector. These are representative data out of 5 ex-
periments. All differences are statistically signiﬁcant according to the one way ANOVA test p b 0.001. Panel C: Immunolocalization of BAX and LEI in BHK overexpressing cells. Cells
transfectedwith the empty vector or cells overexpressing LEI, BAX or bothwere treated (HMA) or not (control)with 40 μMHMA for 18 h. Control cells show a cytoplasmic labelling, treat-
ed cells show different degrees of nuclear labelling. Scale bar represents 10 μm. Representative data out of 4 experiments. Panel D: BHK cells overexpressing or not LEI, BAX or both were
treated (HMA) or not (Ctl)with 40 μMHMA for 18 h. The nuclear fraction of these cells was puriﬁed and aWestern blot was performed. The nuclear localization of LEI/L-DNase II and BAX
was analysed. PR stands for Ponceau Red.
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ence of BAX in the nucleus with HMA treatment, which is unusual. No
nuclear localization signal has been described on BAX [40], suggesting
that the nuclear presence of the BCL-2 family members is probably
due to their interaction with other proteins bearing this signal [41].
Actually, the nuclear localization of BAX has already been described in
the case of a treatment of lung cancer cells by hyperthermia [40,42].
These results added to ours, raise the possibility that BAX may lose its
classical pro-apoptotic function when sequestered to the nucleus.Subsequently, overexpression of the different molecules allowed us to
estimate the functional impact of these interactions on cell survival.
Overexpression of BCL-2 has, as expected, an anti-apoptotic effect,
indicating that other than regulating MMP, it is also able to regulate
mitochondrial independent cell death. We have previously described
that L-DNase II can be activated by cathepsin D after lysosomal
membrane permeabilization [17,43]. This event can also be regulated
by the BCL-2 family of proteins [44]. However, a direct regulation of L-
DNase II by BCL-2 cannot be excluded. Actually, the analysis of LEI and
Fig. 5. Intracellular distribution of LEI. Panel A: BHK cells induced in apoptosis by etoposide
(eto) staurosporin (sts) or HMA (HMA) were fractionated into mitochondrial and cyto-
plasmic fractions. The obtained extracts were developed using anti-LEI. Actin and VDAC
were used to evaluate the purity of the fractions. Only the cytoplasmic pool of LEI is mobi-
lized during L-DNase II mediated apoptosis (Sts and HMA). Panel B: the same experiment
was performed in cells overexpressing BCL-2 (BCL2). Less mobilization of the cytoplasmic
pool of LEI is seen, as quantiﬁed in thehistogram (compare transfected andnot transfected
cells (NT)). Statistics were performed using the one way ANOVA test, followed by the
Newman–Keuls analysis. Only the signiﬁcance of the difference of interest is indicated
(p b 0.005). PR stands for Ponceau Red.
Fig. 6.Molecular structure of LEI and L-DNase II and their putative regulation domain. The
structure of LEI in its native conformation (accession no. NP_109591.1) or in its cleaved
conformation (PDB ID: 1HLE) was represented using the RasMol software. According to
the method of analysis, two regions of putative interaction were identiﬁed 281-311
(green) and 231-254 (red).
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(LAMA) and multiple sequence alignment motifs (blocks) suggests the
existence of an interacting alpha helix in the region 281-311 (Fig. 6,
green) of LEI. However, if a “canonical” interacting sequence is searched
[45] the helix spamming the region 231-254 is also a good candidate
(Fig. 6, red). When analysing the ribbon structure of LEI in its cleaved
or native conformations the spinning of these helixes seems to change,
raising the possibility that the interaction zone between LEI/L-DNase II
and the BCL-2 family depends on its conformation. The same can also
be true for other members of the BCL-2 family and only an interaction
study using puriﬁed molecules in which these helixes are destabilized
by site-directed mutagenesis could give us the answer to this question.
Concerning BAX, overexpression experiments in which LEI and BAX
are overexpressed showed a protection against L-DNase II induced
apoptosis in our paradigm. This result is highly unexpected, as this pro-
tein has beenwidely described as pro-apoptotic [46,47]. Here again, this
is essentially in a caspase dependent cell death context, where BAXwill
form pores releasing pro-apoptotic factors. As we previously pointed
out, in our system, BAX is translocated to the nucleus, a possible
explanation of its lack of pro-apoptotic activity. Actually, the cellular
distribution of BAX is regulated by its interaction with different pro-
teins, some of the BCL-2 family, like BCL-XL [48], but others not belong-
ing to this family of proteins, like Humanin [49] or p53 [41]. Our resultssuggest that BAX can be either pro or anti-apoptotic according to the
context of cell death and depending on which pathways are activated.
This dual functionality has already been found among different proteins
involved in apoptosis. For example, AIF is an anti-apoptotic protein in
the mitochondria via its oxido-reductase activity and it is pro-
apoptotic in the nucleus via its ability to condense DNA [46,47]. LEI/L-
DNase II has also a dual function. LEI is pro-apoptotic with HMA and
staurosporine for instance, due to its transformation into L-DNase II
[50] but it has a protective effect when cells are challenged with
etoposide [25]. In fact, our results reinforce the idea that all pro-
apoptotic proteins have a vital function in the cell [51].
We have previously shown that L-DNase II can interact with themi-
tochondrial protein AIF. This interaction enhances the pro-apoptotic ac-
tivity of both proteins [26]. It has been shown that BCL-2 is also able to
inhibit the AIF pathway [9,52] suggesting that BCL-2 could also be able
to regulate at least, two apoptotic caspase independent pathways: AIF
and LEI/L-DNase II. Moreover, in cases where L-DNase II and AIF are
both activated, having a common inhibitor seems reasonable. However,
this is not the case for BAX. BAX was shown to be an essential factor in
the pro-apoptotic activity of AIF [53,54], but seems to be an inhibitor of
L-DNase II mediated cell death. To date, we have no clues to establish a
hypothesis about the meaning or the physiological signiﬁcance of this
dual function of BAX. This highlights our lack of knowledge onmany as-
pects of the cell death mechanisms.
In conclusion, we show here that the BCL-2 family of proteins is
able to regulate the LEI/L-DNase II pathway, adding this caspase-
independent pathway to other processes that this family of proteins
regulates. These data further insert the LEI/L-DNase II in the network
of cell death to give a more comprehensive picture of the interactions
between the different cell death mechanisms. This is a mandatory step
in the development of new therapeutic weapons for the treatment of
cancer or of degenerative diseases.Acknowledgments
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